ERBB2 and breast carcinoma: HER2-positive breast cancer patients consist of four intrinsic molecular subtypes, luminal A, luminal B, basal-like, and HER2-enriched, the last one being the predominant subtype corresponding to approximately 60–70% of all HER2-positive breast cancers.